SPINAL

Developing Therapy for Acute Spinal Cord Injury

Disability due to spinal cord injury (SCI) is a major global health issue, affecting mainly the young population. Nearly 1.3 million people in the US are living with paralysis due to SCI, and it costs $40.5 billion annually for their care. At present, there is no effective treatment that can achieve functional recovery following SCI.

The pathophysiology of traumatic SCI involves the initial physical impact, which leads to secondary injury cascades of degenerative cellular and molecular events. The secondary injury spreads along the spinal cord over time, which adds new levels of disability and has devastating effects. Reactive oxygen species (ROS) formation at the impact site is an important component of these secondary injury cascades.

ProTransit Spinal Therapy, Inc., is exploring patented technology, Pro-NP™ for its effectiveness to prevent the degenerative events that follows the injury. In a model study, Pro-NP™ was found to be quite effective in regaining locomotive functions when used 3 hrs after the injury.  The company hopes that Pro-NP™ could potentially be administered in the field at the site of incidence or en route to hospital. In addition, Pro-NP™ could potentially be explored in other clinical scenarios where there is a high risk of spinal cord injury.

* Pro-NP™ technology is at a developmental stage and is not available of treating patients at this stage.